Search

Ipratropium

[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.

Trastuzumab

It displays biosimilar properties as Herceptin according to clinical data. … While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer.

Paramethasone

It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less

Clotrimazole

It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). … The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as

Orlistat

It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.

Antithrombin Alfa

Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.

Ferric cation

By mass, it is the most common element on Earth. … deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality if it

LetibotulinumtoxinA

[L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins.

Alcloxa

Palonosetron

As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of